A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).

Nicholas C TurnerMelinda L TelliHope S RugoAudrey MailliezJohannes EttlEva-Maria GrischkeLida A MinaJudith BalmañaPeter Andreas FaschingSara A HurvitzAndrew M WardleyColombe ChappeyAlison L HannahMark E Robsonnull null

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Talazoparib exhibited promising antitumor activity in patients with advanced breast cancer and germline BRCA mutation.

Keyphrases

phase ii study
breast cancer risk
dna repair
open label
locally advanced
randomized controlled trial
clinical trial
dna damage
young adults
rectal cancer